Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Patrick J Hanley; Catherine M Bollard; Claudio G Brunstein

doi:10.1016/j.jcyt.2014.12.007

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Cytotherapy. 2015 Jun;17(6):749-755. doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24.

Authors

Patrick J Hanley¹, Catherine M Bollard², Claudio G Brunstein³

Affiliations

¹ Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA. Electronic address: [email protected].
² Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA.
³ Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: [email protected].

Abstract

Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.

Keywords: antiviral; cell therapy; cord blood; graft-versus-host disease; immunotherapy; regulatory T cells (Treg); transplant.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Fetal Blood / cytology*
Humans
Immunotherapy, Adoptive / methods*
Species Specificity
T-Lymphocytes, Regulatory / immunology*
Viruses / immunology*

Abstract

Publication types

MeSH terms

Grants and funding